1. Home
  2. ICCC vs RFL Comparison

ICCC vs RFL Comparison

Compare ICCC & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$9.91

Market Cap

93.1M

Sector

Health Care

ML Signal

N/A

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

N/A

Current Price

$2.61

Market Cap

92.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ICCC
RFL
Founded
1982
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
93.1M
92.6M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
ICCC
RFL
Price
$9.91
$2.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.5K
92.9K
Earning Date
05-15-2026
06-10-2026
Dividend Yield
N/A
N/A
EPS Growth
53.85
28.28
EPS
0.41
N/A
Revenue
$26,493,169.00
$917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$24.44
N/A
Revenue Growth
51.64
43.96
52 Week Low
$4.52
$1.12
52 Week High
$12.10
$3.96

Technical Indicators

Market Signals
Indicator
ICCC
RFL
Relative Strength Index (RSI) 42.02 62.84
Support Level $9.36 $1.21
Resistance Level $10.75 $3.96
Average True Range (ATR) 0.45 0.17
MACD -0.07 0.06
Stochastic Oscillator 29.56 82.67

Price Performance

Historical Comparison
ICCC
RFL

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: